Regencell Bioscience
5 hedge funds and large institutions have $281K invested in Regencell Bioscience in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
80% more capital invested
Capital invested by funds: $156K → $281K (+$125K)
67% more funds holding
Funds holding: 3 → 5 (+2)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
6.64% less ownership
Funds ownership: 9.22% → 2.58% (-6.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$71.5K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$9.95K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.33K |
| 4 |
BlackRock
New York
|
+$1.31K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$144K |
| 2 |
Morgan Stanley
New York
|
-$22K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $217K | +$71.5K | +259,008 | New |
|
|
2
Royal Bank of Canada
Toronto,
Ontario, Canada
| $30K | +$9.95K | +36,024 | New |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $22.3K | +$7.33K | +26,524 | New |
|
|
4
BlackRock
New York
| $11.6K | +$1.31K | +4,750 | +53% |
|
|
5
Morgan Stanley
New York
| $159 | -$22K | -79,610 | -100% |
|
|
6
UBS Group
Zurich,
Switzerland
| – | -$144K | -1,110,284 | Closed |
|
RGC Hedge Fund Activity: Q1 2025 in Review
5 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q1 2025, worth a combined $281K — up 80% from $156K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new RGC positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $71.5K. The largest seller was UBS Group, exiting entirely with an estimated $144K sold.
- 5 institutional investors held Regencell Bioscience (RGC) as of Q1 2025, up from 3 in Q4 2024.
- Funds reported $281K of Regencell Bioscience stock for Q1 2025, up 80% quarter-over-quarter.
- 3 funds opened new Regencell Bioscience positions in Q1 2025 and 1 closed out, a net change of +2 holders.
- The largest Regencell Bioscience buyer in Q1 2025 was Geode Capital Management, an estimated $71.5K added.
- The largest Regencell Bioscience seller in Q1 2025 was UBS Group, an estimated $144K sold.
Based on aggregated 13F filings for Q1 2025.